Aadi Bioscience ( (AADI) ) has issued an announcement.
On March 4, 2025, Aadi Bioscience completed a $100 million private placement, led by Ally Bridge Group and involving several new and existing investors. This financing, alongside the sale of its FYARRO business, is expected to fund Aadi’s operations into 2028, supporting clinical data readouts for its ADC portfolio. Additionally, a special meeting held on February 28, 2025, saw shareholders approve several proposals, including the sale of Aadi Subsidiary, Inc. to KAKEN INVESTMENTS INC., and an amendment to the company’s equity incentive plan.
More about Aadi Bioscience
Aadi Bioscience is a precision oncology company focused on applying advanced technologies to established tumor biology, aiming to deliver improved therapies for difficult-to-treat cancers.
YTD Price Performance: -18.47%
Average Trading Volume: 363,469
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $63.22M
For a thorough assessment of AADI stock, go to TipRanks’ Stock Analysis page.